Home
Resources
Follow portfolio news
...

ScreenPoint Medical facilitates breast cancer diagnosis in Washington State

Published on
18/12/2025
Amended on
23/3/2026
0
minute(s)
Odyssey 2021
ScreenPoint Medical
ScreenPoint Medical, a company featured in the Vintage Altaroc Odyssey , is seeing its AI technology take on a new dimension thanks to its launch in RAYUS Radiology centers in Washington State. Already used for more than ten million mammograms worldwide, the Dutch company's AI provides radiologists with an additional tool to detect certain signs of breast cancer earlier.
By
Antoine Orsoni
Antoine Orsoni
ScreenPoint Medical facilitates breast cancer diagnosis in Washington State
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
Questo articolo è stato tradotto automaticamente. Ci scusiamo per eventuali inesattezze o errori di traduzione.

The national RAYUS group offers imaging examinations in many cities and invests in innovative technologies to improve the quality of diagnoses. It has selected ScreenPoint Medical's AI ScreenPoint Medical, trained on a vast dataset comprising one million images and 15,000 cancer cases from various mammography models and different medical centers. For patients, the experience remains the same. The AI is integrated directly into the appointment process without any additional steps or extended waiting times.  According to radiologist Kara L. Carlson, AI acts as a second reader and is useful for patients with high breast density, a condition that can make some screenings more difficult. Kara L. Carlson is an American radiologist specializing in breast imaging with over 30 years of experience, combining clinical expertise and a commitment to innovation, notably as head of the RAYUS Radiology Issaquah Breast Imaging center (specializing in breast cancer detection). She has been recognized several times as a " Top Doctor " by her peers, an accolade that highlights the excellence and lasting impact of her career.

The arrival of this technology marks a significant advance in breast cancer screening. Dr. Kellie Schenk points out that the goal is not to replace radiologists but to enhance their work. AI improves consistency and accuracy, while leaving the final judgment to doctors. This combination of human expertise and innovative tools paves the way for more reliable screening that is more attentive to patients' needs. RAYUS Radiology already plans to offer this service in other parts of the country in the coming months. The company is continuing to invest in improving breast health nationwide and providing every patient with access to increasingly safe and effective examinations.

Founded in 2014 in the Netherlands by Nico Karssemeijer and Michael Brady, specialists in breast imaging, machine learning, and computer-aided detection, ScreenPoint Medical brought together a team of experts from the outset to develop a decision support algorithm. Their main goal is to facilitate early detection of breast cancer in order to improve survival rates and promote less invasive treatments, with the ultimate aim of saving lives. The MASAI trial (conducted as part of Sweden's national breast cancer screening program) showed that with ScreenPoint Medical's AI, equipped medical centers detected 29% more cancers while reducing the reading burden on radiologists by 44%.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
North America
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.